“…To date, there have not been many studies on this compound, except for its inhibition of acute inflammation and hyperalgesia ( Roslida, 2004 ). We had previously reported multiple studies on the plant’s root hexane and its fractionated extracts enriched with this aforementioned compound, labelled as ACRH and QRF, respectively, including anti-inflammatory, anti-arthritic, antitumor promotion and antiangiogenic ( Roslida and Kim, 2008 , Roslida et al, 2009 , Lau et al, 2009 , Roslida et al, 2011 , Sulaiman et al, 2012 , Hamid et al, 2013 , Hamsin et al, 2013 , Hamsin et al, 2014 , Yeong et al, 2013 , Yeong et al, 2014 , Yeong et al, 2015 , Hamid et al, 2017 , Wen Jun et al, 2019 , Blin et al, 2021a , Blin et al, 2021b ), However, little was known about the principal bioactive compound in ACRH and QRF that might also be responsible for its antiangiogenic property and the possible pathway involved. Therefore, in the current study, we isolated the compound and tested it in various in vitro angiogenesis and in vivo zebrafish assays, as well as in elucidating the potential protein targets responsible for the antiangiogenic effect of AC2.…”